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Background: Previous randomised controlled trials of high dose oral corticosteroids
in cystic ﬁbrosis (CF) have reported serious adverse effects including decreased
growth. The long term effects of regular low dose oral corticosteroids on growth
are less clear.
Aims: To describe the long term effects on growth of low dose oral steroids on
children with CF.
Methods: Case control comparison of growth of subjects receiving regular oral
steroids for greater than 6 months, and age and sex matched controls. Height,
weight and body mass index (BMI) were collected, and standard deviation scores
(SDS) calculated. For each subject the slope of change in height, weight and BMI
SDS was calculated by linear regression for 24 months before commencing steroids,
and for the period after starting steroids.
Results: 28 cases and 28 controls were identiﬁed, with no signiﬁcant differences
between the two groups at baseline. Mean duration of follow up data was 4 years
for both groups. Mean daily dose of prednisolone was 0.15mg/kg. There were no
signiﬁcant differences in slope of weight or BMI SDS between groups. There was
a signiﬁcant difference in slope of height SDS between the cases and controls after
commencing steroids (−0.12 v 0.02 SDS/yr; 95% CI diff −0.24, −0.01; p = 0.032).
Growth suppression was greatest in the ﬁrst year (−0.17 v 0.10 SDS/yr, 95% CI
diff −0.47, −0.07; p = 0.008), and there was no signiﬁcant difference in change
in height SDS in the subsequent 2 (−0.06 v −0.10 SDS/yr; p = 0.6) or 4 years
(−0.03 v −0.04 SDS/yr; p = 0.9).
Conclusions: Use of regular low dose oral steroids in CF has a short term effect
on growth, but thereafter growth appears normal.
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Background: Inhaled corticosteroids (ICS) are frequently prescribed to patients
with cystic ﬁbrosis (CF) without clear evidence of efﬁcacy in the treatment of lung
disease. In the Belgian CF Registry, nearly 50% of the patients are reported to use
ICS. A previous mixed model analysis of the Belgian CF patients has shown that
ICS use is associated with a reduction in the rate of FEV1 decline but this was
accompanied by a lower yearly growth (3mm per year).
Objectives: The objective of the study is to analyse the long-term effects on growth
of ICS taken by CF patients during childhood and adolescence by reporting their
adult height.
Methods: The adult height of 31 patients never taking ICS (no-ICS group) was
compared to that of 40 patients using ICS >50% of time (ICS group). ICS use was
documented at least 3 years before attaining adult height. Patients with a transplant
and those using oral steroids were excluded. Adult height was expressed in SDS
according to CDC references. 55% were F508del homozygous.
Results: Mean adult height SDS was similar in the 2 groups and was respectively
−0.28±0.82 SDS in the no-ICS group (at 18.4±2.1 years) and −0.49±1.05. SDS in
the ICS group (at 18.6±1.7 years) after a mean follow-up period until adult height
of 6.2±1.8 years. Mean FEV1 % predicted obtained at adult height was lower
(67.0±20.6%) in the ICS group than in the no-ICS group (83.4±21.3%) p = 0.002.
Conclusions: This analysis of long term ICS use shows no difference in adult height
between CF patients who never used ICS and those who used ICS during more than
50% of the study period. As previously reported ICS appear preferentially used in
patients with worse lung function.
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The importance of nutritional care in cystic ﬁbrosis (CF) is well recognised. Mal-
nutrition in CF is associated with poorer pulmonary function and is an independent
risk factor for poor survival.
In order to compare the nutritional status of adults attending the Prince Charles
Adult CF Centre in 2009 versus 1999 a retrospective chart audit of 212 patients
was completed. Data including nutritional status, pancreatic enzyme replacement
therapy (PERT) usage, glucose tolerance and dietetic review was collected.
This audit found a signiﬁcant improvement in mean BMI (21.1±3.0 versus
22.5±3.8; p = 0.0017), reﬂecting an improved nutritional status over the 10 year
period. Prevalence of abnormal glucose tolerance has increased (12% versus 26%;
p = 0.004) most likely due to a vigilant screening program commenced in 2000. Use
of commercial oral supplements is higher, notably the percentage of patients using
commercial oral supplements in 2009 (26% versus 45%; p = 0.00001), is higher
than identiﬁed in the recent DAA survey of nutrition management practices of
Australian Dietitians at 18%. Annual dietetic review is also a statistically signiﬁcant
change (73% versus 90% p= 0.00009), this increased review rate despite a two fold
increase in the overall CF population may be attributable to a stable and experienced
workforce as the dietetic stafﬁng and FTE has remained stable over the 10 year
period.
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Introduction: Optimal nutritional management is essential in optimizing quality of
life and survival in CF. Since 2004, a dietician has been dedicated to our CF patients.
Objective: To evaluate changes in the nutritional status of the CF patients cared at
our adult CF centre.
Method: We compared the nutritional status of 301 patients seen in 2007 with that
of 163 patients seen in 1997. Malnutrition was deﬁned as BMI< 18.5 and severe
malnutrition as BMI< 16 kg/m2.
Results: In 2007, mean age was 29.3 yrs (vs 28.8 yrs in 1997). Mean BMI was
20.8±2.3 and 20.1±3.4 kg/m2 in men and women, respectively (vs 19.2±3.0 and
19.1±2.6 kg/m2 in 1997). Malnutrition was seen in 77 patients (25.6% as compared
to 49.7% in 1997). Severe malnutrition was found in 13 patients (4.3% vs 22.1% in
1997). Malnutrition was more frequent in females (48 patients, 32.6%) than in males
(29 patients, 18.8%). This was even more pronounced for severe malnutrition, found
in 10 females (6.8%) and 3 males (2.0%). The frequency of exocrine pancreatic
insufﬁciency was unchanged (80.4% vs 83.4% in 1997). Diabetes mellitus was more
frequent in 2007 (23.9%) than in 1997 (18.4%), probably because it was detected
more actively. More females (33%) than males (16%) had diabetes. Hepatic cirrhosis
was present in 6.6% of the patients (vs 9.8 % in 1997). Enteral nutrition had been
used in 19 patients, 6.3% (vs 6.7% in 1997). The respiratory function had improved,
with mean FEV1 56.3±24.5% pred., as compared to 47.1±25.5% pred. in 1997.
Conclusion: Nutritional status and respiratory function have improved in our
CF patients over those last 10 years, probably thanks to a more active dietary
management.
